Overview

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Status:
Completed

Trial end date:
2020-04-20

Target enrollment:

Participant gender:

Summary

The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.

Phase:

Phase 3

Details

Lead Sponsor:

Actelion

Treatments:

Macitentan
Selexipag
Tadalafil